Xgeva 120 MG/1.7 ML vial 1.7ML
Ended Awarded
- Contract number
- SPE2DB25FCZMU
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $26,264
Award facts
- Contract value 100% obligated
- $26,263.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $26,263.60 to AmerisourceBergen Drug Corp for the supply of XGEVA 120 mg/1.7 mL vials. The contract, issued on August 13, 2025, with an ultimate completion date of August 14, 2025, operates under firm fixed pricing with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026.
XGEVA (denosumab) is a prescription medication used to treat hypercalcemia and bone loss associated with certain cancers and conditions, making this acquisition part of the Defense Logistics Agency's comprehensive pharmaceutical supply chain supporting military healthcare systems. AmerisourceBergen's role as a major pharmaceutical distributor positions it as a critical vendor for federal medical procurement, with its DLA Troop Support Medical IDC serving as a global pharmaceutical support vehicle enabling the supply of branded and generic medications, vaccines, and specialized medical supplies to support military healthcare programs worldwide. The firm fixed price structure and rapid completion timeline reflect the standard operational model for urgent pharmaceutical delivery orders within the DLA Medical Supply Chain.
Quick answers
Who was awarded contract SPE2DB25FCZMU?
SPE2DB25FCZMU was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 13, 2025.
How much is contract SPE2DB25FCZMU worth?
The government has obligated $26,264 on SPE2DB25FCZMU.
Is contract SPE2DB25FCZMU an order under another contract?
Yes. SPE2DB25FCZMU is a delivery order under SPE2DB24D1205, an indefinite delivery contract.
Was contract SPE2DB25FCZMU competed?
The extent of competition for SPE2DB25FCZMU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award